Please assess the completion status of the following clinical trial:

Trial Title: Effect of Docosahexaenoic Acid (DHA)-Enriched Human Milk in Premature Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Childbirth between 34 and 35 GA~* Breast-feeding~* Caucasian~* Affiliation to social security~* Obtained consent from mother, and parents for the child~* Mother with balanced diet~* No allergy to eggs~* Single pregnancy~Exclusion Criteria:~* Allergy to egg~* Unbalanced diet~* Diabetes~* Known digestive disease~* Counter-indication with breast-feeding~* Cigarettes (more than 5 per day)~* Alcoholism (daily consumption of alcohol)~* Multiple pregnancy

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- TG-DHA (Type: ACTIVE_COMPARATOR): TG-DHA: lactating mothers and their newborn with mothers supplemented with Triglyceride enriched in docosahexaenoic acid
- Control (Type: NO_INTERVENTION): Control: lactating mothers and their newborn with no supplementation given to the mother
- GPL-DHA (Type: EXPERIMENTAL): GPL-DHA: lactating mothers and their newborn with mothers supplemented with Glycerophospholipid enriched in docosahexaenoic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).